Syncope, or transient loss of consciousness, is a common clinical problem with a broad spectrum of potential causes, making its diagnosis and management complex. This article aims to provide a comprehensive approach to the clinical evaluation and management of syncope.
Syncope can be categorized into three main etiologies: cardiogenic, reflex (neurally mediated), and orthostatic hypotension. The diagnostic approach should start with a detailed history and physical examination, focusing on the circumstances preceding the syncopal event, associated symptoms, and risk factors for cardiovascular disease. This initial evaluation can guide further diagnostic testing, which may include electrocardiogram (ECG), Holter monitoring, tilt table test, or cardiac imaging.
The management of syncope is determined primarily by the underlying cause. Cardiogenic syncope may require hospitalization, specific medical therapies, or device implantation. Reflex syncope is often managed conservatively with patient education, avoidance of triggers, and physical counterpressure maneuvers. In cases of orthostatic hypotension, treatment involves volume expansion, physical countermeasures, and pharmacological therapy when necessary.
Risk stratification is crucial in the management of syncope. High-risk features, such as older age, history of heart disease, abnormal ECG, or syncope during exertion, may necessitate urgent evaluation and intervention. Conversely, patients without these features can often be managed on an outpatient basis.
Syncope is a multifaceted clinical problem that requires a systematic approach for effective diagnosis and management. By understanding the potential etiologies, employing appropriate diagnostic tools, implementing tailored management strategies, and accurately stratifying risk, healthcare providers can ensure optimal patient outcomes in the face of this common but complex condition.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation